Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 10.727
Filter
1.
Syst Rev ; 13(1): 108, 2024 Apr 16.
Article in English | MEDLINE | ID: mdl-38627798

ABSTRACT

BACKGROUND: Leptospirosis, an important zoonotic bacterial disease, commonly affects resource-poor populations and results in significant morbidity and mortality worldwide. The value of antibiotics in leptospirosis remains unclear, as evidenced by the conflicting opinions published. METHODS: We conducted a search in the PubMed, Web of Science, and Cochrane Library databases for studies. These studies included clinical trials and retrospective studies that evaluated the efficacy or safety of antibiotics for leptospirosis treatment. The primary outcomes assessed were defervescence time, mortality rate, and hospital stays. Subgroup analyses were performed based on whether there were cases involving children and whether there were cases of severe jaundice. Safety was defined as the prevalence of adverse events associated with the use of antibiotics. p scores were utilized to rank the efficacy of the antibiotics. RESULTS: There are included 9 randomized controlled trials (RCTs), 1 control trial (CT), and 3 retrospective studies (RS) involving 920 patients and 8 antibiotics. Six antibiotics resulted in significantly shorter defervescence times compared to the control, namely cefotaxime (MD, - 1.88; 95% CI = - 2.60 to - 1.15), azithromycin (MD, - 1.74; 95% CI = - 2.52 to - 0.95), doxycycline (MD, - 1.53; 95% CI = - 2.05 to - 1.00), ceftriaxone (MD, - 1.22; 95% CI = - 1.89 to - 0.55), penicillin (MD, - 1.22; 95% CI = - 1.80 to - 0.64), and penicillin or ampicillin (MD, - 0.08; 95% CI = - 1.01 to - 0.59). The antibiotics were not effective in reducing the mortality and hospital stays. Common adverse reactions to antibiotics included Jarisch-Herxheimer reaction, rash, headache, and digestive reactions (nausea, vomiting, diarrhea, abdominal pain, and others). CONCLUSIONS: Findings recommend that leptospirosis patients be treated with antibiotics, which significantly reduced the leptospirosis defervescence time. Cephalosporins, doxycycline, and penicillin are suggested, and azithromycin may be a suitable alternative for drug-resistant cases. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022354938.


Subject(s)
Anti-Bacterial Agents , Leptospirosis , Humans , Anti-Bacterial Agents/adverse effects , Azithromycin/adverse effects , Doxycycline/therapeutic use , Leptospirosis/drug therapy , Leptospirosis/chemically induced , Network Meta-Analysis , Penicillins/therapeutic use
2.
BMJ Case Rep ; 17(4)2024 Apr 02.
Article in English | MEDLINE | ID: mdl-38569736

ABSTRACT

A healthy man in his late 20s was admitted to the emergency department due to a flare-up in his severe chronic stomatitis, along with flu-like symptoms. CXR showed multiple bilateral consolidations and subsequent CT revealed thrombosis of the left facial and internal jugular vein, together with septic embolism in both lungs. Blood cultures showed penicillin-susceptible Staphylococcus aureus The patient was diagnosed with Lemierre's syndrome, despite atypical bacteria and clinical presentation. During hospitalisation, he developed pulmonary empyema as a complication and was admitted for 4 weeks. During hospitalisation and after discharge, the patient was examined for multiple rheumatic, immunological and dermatological diseases, but no underlying cause for Lemierre's syndrome has been found. We present this case due to the rarity of its nature, with atypical clinical presentation and pathogen for Lemierre's syndrome, but with classic radiological findings.


Subject(s)
COVID-19 , Lemierre Syndrome , Staphylococcal Infections , Male , Humans , Staphylococcus aureus , Lemierre Syndrome/complications , Lemierre Syndrome/drug therapy , Lemierre Syndrome/diagnosis , Penicillins/therapeutic use , COVID-19/complications , Staphylococcal Infections/complications , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapy
3.
Helicobacter ; 29(2): e13073, 2024.
Article in English | MEDLINE | ID: mdl-38601987

ABSTRACT

BACKGROUND: Helicobacter pylori infection and its associated diseases represent a significant global health concern. Patients who cannot use amoxicillin pose a therapeutic challenge and necessitate alternative medications. Preliminary research indicates that cefuroxime demonstrates promising potential for eradicating H. pylori infection, and there is a lack of comprehensive review articles on the use of cefuroxime. MATERIALS AND METHODS: This study conducts a thorough systematic literature review and synthesis. A comprehensive systematic search was conducted in PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, China Biology Medicine disc, and Wanfang Data up to January 13, 2024. The search strategy utilized the following keywords: (Cefuroxime) AND (Helicobacter pylori OR Helicobacter nemestrinae OR Campylobacter pylori OR Campylobacter pylori subsp. pylori OR Campylobacter pyloridis OR H. pylori OR Hp) for both English and Chinese language publications. Sixteen studies from five different countries or regions were included in final literature review. RESULTS: Analysis results indicate that H. pylori is sensitive to cefuroxime, with resistance rates similar to amoxicillin being relatively low. Regimens containing cefuroxime have shown favorable eradication rates, which were comparable to those of the regimens containing amoxicillin. Regarding safety, the incidence of adverse reactions in cefuroxime-containing eradication regimens was comparable to that of amoxicillin-containing regimens or other bismuth quadruple regimens, with no significant increase in allergic reactions in penicillin-allergic patients. Regarding compliance, studies consistently report high compliance rates for regimens containing cefuroxime. CONCLUSION: Cefuroxime can serve as an alternative to amoxicillin for the patients allergic to penicillin with satisfactory efficacies, safety, and compliance.


Subject(s)
Helicobacter Infections , Helicobacter pylori , Humans , Helicobacter Infections/drug therapy , Cefuroxime/therapeutic use , Anti-Bacterial Agents/adverse effects , Drug Therapy, Combination , Amoxicillin/therapeutic use , Bismuth/adverse effects , Penicillins/therapeutic use , Treatment Outcome , Proton Pump Inhibitors/therapeutic use
5.
BMJ ; 384: q595, 2024 03 08.
Article in English | MEDLINE | ID: mdl-38458645
6.
Ital J Pediatr ; 50(1): 29, 2024 Feb 14.
Article in English | MEDLINE | ID: mdl-38355651

ABSTRACT

Notifications of invasive group A streptococcal (iGAS) infections have significantly increased in many European Countries compared to the previous season. In Italy, there has been an increase in streptococcal pharyngitis and scarlet fever cases since January 2023, which sparked concerns about a GAS epidemic in the pediatric population. This rise may be ascribed to the GAS infection season that began earlier than usual (off-season outbreak) and the increase in the spread of respiratory viruses and viral coinfections that raised the risk of iGAS disease. Moreover, this phenomenon was also facilitated by increased travel after reduced GAS circulation during the COVID-19 pandemic.The increase in cases of GAS disease has raised some critical issues regarding the potential reactions to administering amoxicillin, the first-line antibiotic therapy, many of which have been erroneously labeled as "allergy."For these reasons, the Italian Society of Pediatric Allergy and Immunology (SIAIP) intends to provide simple clinical indications to help pediatricians manage GAS pharyngitis, discerning the allergic from non-allergic drug hypersensitivity.


Subject(s)
Drug Hypersensitivity , Hypersensitivity , Pharyngitis , Scarlet Fever , Streptococcal Infections , Child , Humans , Scarlet Fever/drug therapy , Pharynx , Pandemics , Pharyngitis/drug therapy , Penicillins/therapeutic use , Anti-Bacterial Agents/adverse effects , Streptococcal Infections/diagnosis , Streptococcal Infections/drug therapy , Drug Hypersensitivity/diagnosis , Hypersensitivity/drug therapy
7.
Curr Opin Obstet Gynecol ; 36(2): 67-74, 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-38205786

ABSTRACT

PURPOSE OF REVIEW: While the clinical disease of syphilis, its consequences in pregnancy, and its sensitivity to penicillin treatment have remained relatively unchanged for a century or more, new technologies and basic discoveries in syphilis research have translated into tangible advances in clinical diagnosis, treatment, and prevention. The purpose of this review is to help the reader understand some of the recent relevant scientific publications on syphilis and its causative organism in a clinical obstetric context. RECENT FINDINGS: Rates of adult and congenital syphilis have risen dramatically in the last decade despite public health efforts. Penicillin shortages and lack of screening or adequate treatment have all contributed to global disease burden. Advances in genomic and microbiological characterization of this spirochete have led to new developments in serologic and molecular diagnosis as well as evaluation of potential vaccine candidates. Until a syphilis vaccine is available, substance use disorders and lack of screening in pregnancy are associated with increased congenital syphilis, and these challenges will require novel solutions to fully address this public health crisis. SUMMARY: Addressing the burden of congenital syphilis demands that obstetricians stay well informed of new tools and resources for diagnosis, treatment, and prevention of syphilis now and in the future.


Subject(s)
Pregnancy Complications, Infectious , Syphilis, Congenital , Syphilis , Vaccines , Pregnancy , Adult , Female , Humans , Syphilis/diagnosis , Syphilis/drug therapy , Syphilis/prevention & control , Syphilis, Congenital/diagnosis , Syphilis, Congenital/prevention & control , Syphilis, Congenital/drug therapy , Anti-Bacterial Agents/therapeutic use , Public Health , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/drug therapy , Pregnancy Complications, Infectious/prevention & control , Penicillins/therapeutic use , Vaccines/therapeutic use
8.
Ophthalmic Surg Lasers Imaging Retina ; 55(1): 46-50, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38189796

ABSTRACT

A 23-year-old man developed bilateral rhegmatogenous retinal detachments secondary to high-titer ocular syphilis. The patient's titer increased four-fold after completing a 14-day course of intravenous penicillin (IVP). He underwent bilateral pars plana vitrectomy with silicone oil fill in both eyes. In this article, the authors propose an updated treatment method for patients with advanced ocular syphilis that includes oral doxycycline for 30 days following 14 days of IVP to optimally minimize the patient's infectious burden. Following surgery and this new treatment regime, this patient's best-corrected visual acuity 10 weeks postoperatively measured 20/50 in the right eye and 20/30 in the left eye. This case highlights a rare but devastating complication of ocular syphilis. We suggest the addition of oral doxycycline to IVP for patients with syphilis titers ≥ 1:256, HIV co-infection, and presence of posterior retinitis. [Ophthalmic Surg Lasers Imaging Retina 2024;55:46-50.].


Subject(s)
Endophthalmitis , Eye Infections, Bacterial , Retinal Detachment , Syphilis , Humans , Male , Young Adult , Doxycycline , Eye , Eye Infections, Bacterial/complications , Eye Infections, Bacterial/diagnosis , Penicillins/therapeutic use , Retinal Detachment/diagnosis , Retinal Detachment/etiology , Syphilis/complications , Syphilis/diagnosis
9.
J Am Vet Med Assoc ; 262(2): 232-240, 2024 Feb 01.
Article in English | MEDLINE | ID: mdl-37972477

ABSTRACT

OBJECTIVE: To describe the clinical findings, microbiological data, treatment, and outcome of a population of cats with suspected acute pyelonephritis (APN). ANIMALS: 32 client-owned cats. CLINICAL PRESENTATION AND PROCEDURES: Retrospective case series from 2 veterinary teaching hospitals between January 1, 2014, and December 31, 2020. Cats were included if they had a positive bacterial urine culture and a clinical diagnosis of acute kidney injury. RESULTS: Older female cats with underlying chronic kidney disease have a higher probability to develop bacterial culture-positive acute kidney injury or APN. Escherichia coli was the most commonly cultured bacterial species, and E coli isolates with susceptibility testing were resistant to amoxicillin-clavulanate but susceptible to fluoroquinolones or third-generation cephalosporins. Of the 20 cats with available follow-up information in the medical record, 14 were alive at 3 months after hospital discharge. Markers of renal function including creatinine (P = .008), BUN (P = .005), and phosphorus (P < .001) at the time of presentation were all higher in nonsurvivors compared with survivors. CLINICAL RELEVANCE: The survival rate with feline APN is higher than previous reports of acute kidney injury when all etiologies are considered. Nonsurvivors had more pronounced azotemia upon initial presentation. Amoxicillin-clavulanate was a poor empirical antimicrobial in this cohort based on the microbiological data.


Subject(s)
Acute Kidney Injury , Cat Diseases , Escherichia coli Infections , Pyelonephritis , Humans , Cats , Animals , Female , Escherichia coli , Anti-Bacterial Agents/therapeutic use , Escherichia coli Infections/complications , Escherichia coli Infections/drug therapy , Escherichia coli Infections/veterinary , Penicillins/therapeutic use , Retrospective Studies , Pyelonephritis/drug therapy , Pyelonephritis/veterinary , Pyelonephritis/epidemiology , Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Prognosis , Acute Kidney Injury/veterinary , Cat Diseases/drug therapy
10.
Int J Oral Maxillofac Surg ; 53(3): 251-257, 2024 Mar.
Article in English | MEDLINE | ID: mdl-37758642

ABSTRACT

This retrospective analysis was performed to investigate whether clindamycin remains the preferred antibiotic for penicillin-allergic patients with odontogenic infections. The medical records of 311 patients admitted to the study department with odontogenic infections between 2018 and 2022 and treated with either intravenous amoxicillin-clavulanic acid (Augmentin) or intravenous clindamycin were analyzed. The Augmentin-treated group included 268 patients (86.2%) and the clindamycin-treated group included 43 patients (13.8%). Severity parameters did not differ significantly between the two groups, except for a higher prevalence of abscesses in the clindamycin-treated group (58.1% vs 41.0% in the Augmentin-treated group; P = 0.035). The clindamycin-treated group required a longer duration of intravenous antibiotics (P = 0.001) and had a higher rate of treatment failure (14.0% vs 2.2%; P = 0.002) when compared to the Augmentin-treated group, with a seven-fold increased risk of treatment failure. Moreover, significantly more isolated organisms in the clindamycin-treated group were resistant to clindamycin (P = 0.015); these were all Streptococcus anginosus group. Given the higher risk of treatment failure with clindamycin, it is necessary to choose the antibiotic treatment for penicillin-allergic patients carefully. A detailed history and allergy testing followed by combination therapy is recommended, especially in severe cases.


Subject(s)
Clindamycin , Penicillins , Humans , Penicillins/therapeutic use , Clindamycin/therapeutic use , Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Retrospective Studies , Anti-Bacterial Agents/therapeutic use
11.
Sex Transm Dis ; 51(1): 81-83, 2024 01 01.
Article in English | MEDLINE | ID: mdl-38100818

ABSTRACT

ABSTRACT: Syphilis has long been considered the "great masquerader," notorious for its varying presentations and ability to affect most organ systems in the body. We report the case of a 41-year-old immunocompetent man who presented to ophthalmology with rapidly progressive visual complaints from bilateral panuveitis and concomitant verrucous facial lesions initially disregarded by the patient as acne. Serum testing for syphilis was positive, and he was admitted for 14 days of intravenous (IV) penicillin with multiservice care from dermatology, ophthalmology, and infectious disease. We present photographic documentation showing his stepwise resolution of his facial and retinal involvement with penicillin treatment course. This case is unusual in the concomitant presentation of ocular and facial syphilitic findings in an immunocompetent patient and highlights the need to include syphilis in the differential for unusual appearances.


Subject(s)
Anti-Bacterial Agents , Penicillins , Retinal Diseases , Skin Diseases, Bacterial , Syphilis , Adult , Humans , Male , Penicillins/therapeutic use , Syphilis/diagnosis , Syphilis/drug therapy , Syphilis/complications , Face , Retinal Diseases/drug therapy , Retinal Diseases/etiology , Retinal Diseases/microbiology , Skin Diseases, Bacterial/drug therapy , Skin Diseases, Bacterial/etiology , Skin Diseases, Bacterial/microbiology , Anti-Bacterial Agents/therapeutic use
12.
J Med Case Rep ; 17(1): 549, 2023 Dec 22.
Article in English | MEDLINE | ID: mdl-38129918

ABSTRACT

BACKGROUND: Crescentic glomerulonephritis with syphilis infection is rare, and the mechanism underlying the formation of glomerular capillary wall damage-induced crescent has not been elucidated. CASE PRESENTATION: A 62-year-old Japanese male showed edema, eruption, and rapid deterioration of the renal function after an acute syphilis infection. A renal biopsy showed crescentic glomerulonephritis with C3 deposition in the glomerular capillary wall, and immunostaining for anti-Treponema pallidum antibody was weakly positive in some interstitium and one glomerulus. Electron microscopy revealed the presence of string-shaped structures in the glomerular capillary walls. After treatment with penicillin followed by prednisolone, the renal function and urinary abnormalities, including Treponema pallidum protein, disappeared. CONCLUSIONS: Crescentic glomerulonephritis associated with syphilis showed a string-shaped deposition in the glomerular capillary and urinary Treponema pallidum protein excretion, and was effectively treated with penicillin and prednisolone.


Subject(s)
Glomerulonephritis , Syphilis , Humans , Male , Middle Aged , Acute Disease , Glomerulonephritis/complications , Glomerulonephritis/drug therapy , Kidney Glomerulus/blood supply , Kidney Glomerulus/pathology , Penicillins/therapeutic use , Prednisolone/therapeutic use , Syphilis/complications , Syphilis/diagnosis , Syphilis/drug therapy
13.
N Z Med J ; 136(1586): 84-93, 2023 Dec 01.
Article in English | MEDLINE | ID: mdl-38033243

ABSTRACT

AIM: Acute rheumatic fever (ARF), a serious inflammatory condition, often leads to rheumatic heart disease (RHD). Between 2011 and 2016, Aotearoa New Zealand implemented a rheumatic fever prevention programme (RFPP) to reduce high rates of ARF through improved community access to timely diagnosis and early treatment of group A streptococcal (GAS) pharyngitis, which has been shown to prevent subsequent ARF. This study aimed to quantify the change in penicillin antibiotic dispensing rates among children aged 18 years or younger during the RFPP. METHOD: This retrospective analysis utilised administrative data from the National Pharmaceutical Collection. Using a controlled, interrupted time series analysis, the effect of the RFPP on antibiotic dispensing rates was explored. Poisson regression models were used to assess the change in dispensing rates during the RFPP among control regions (those not in the RFPP) and regions participating in the RFPP. The primary measure was rate ratio (RR) for the difference between the observed versus counterfactual rates of penicillin dispensing. RESULT: A total of 12,154,872 dispensing records between 2005 and 2018 were included. Amoxicillin was the most frequently dispensed penicillin (57.7%), followed by amoxicillin-clavulanate (23.4%). Amoxicillin dispensing increased by 4.3% in regions operating the RFPP compared to the increase in control regions (p<0.001). The overall rate of penicillin dispensing decreased, driven by a rapid decline in amoxicillin-clavulanate dispensing. CONCLUSION: During the RFPP an increase in amoxicillin dispensing was seen in regions participating in the programme and regions outside of the programme, indicating the programmatic approach led to improved adherence to recommended first-line antibiotics.


Subject(s)
Rheumatic Fever , Rheumatic Heart Disease , Child , Humans , Rheumatic Fever/drug therapy , Rheumatic Fever/prevention & control , Penicillins/therapeutic use , Retrospective Studies , New Zealand , Anti-Bacterial Agents/therapeutic use , Amoxicillin , Amoxicillin-Potassium Clavulanate Combination
14.
J Infect Dis ; 228(Suppl 4): S249-S258, 2023 10 03.
Article in English | MEDLINE | ID: mdl-37788506

ABSTRACT

Although nearly a century has elapsed since the discovery of penicillin, bacterial infections remain a major global threat. Global antibiotic use resulted in an astounding 42 billion doses of antibiotics administered in 2015 with 128 billion annual doses expected by 2030. This overuse of antibiotics has led to the selection of multidrug-resistant "super-bugs," resulting in increasing numbers of patients being susceptible to life-threatening infections with few available therapeutic options. New clinical tools are therefore urgently needed to identify bacterial infections and monitor response to antibiotics, thereby limiting overuse of antibiotics and improving overall health. Next-generation molecular imaging affords unique opportunities to target and identify bacterial infections, enabling spatial characterization as well as noninvasive, temporal monitoring of the natural course of the disease and response to therapy. These emerging noninvasive imaging approaches could overcome several limitations of current tools in infectious disease, such as the need for biological samples for testing with their associated sampling bias. Imaging of living bacteria can also reveal basic biological insights about their behavior in vivo.


Subject(s)
Bacterial Infections , Humans , Bacterial Infections/diagnostic imaging , Bacterial Infections/drug therapy , Anti-Bacterial Agents/therapeutic use , Bacteria , Penicillins/therapeutic use , Molecular Imaging
15.
Dermatologie (Heidelb) ; 74(11): 858-863, 2023 Nov.
Article in German | MEDLINE | ID: mdl-37851090

ABSTRACT

The guidelines on calculated parenteral initial treatment of bacterial infections in adults from 2018 were the first German language S2k guidelines for these infections. This article summarizes the experiences with respect to their practicality in the clinical routine and the resulting supplementations and comments. In view of the many different terms for soft tissue infections, the guidelines had to first establish some definitions and diagnostic criteria. Among others, the guidelines introduced the provisional term limited phlegmons (phlegmons are usually termed cellulitis in Angloamerican literature) for the frequent initially superficial soft tissue infections with Staphylococcus aureus, which do not always extend to the fascia, in order to differentiate them from erysipelas caused by Streptoccocus, which in contrast to phlegmons always respond to penicillin. The general symptoms present in erysipela are a practical differential criterion. Somewhat more complex are the definitions and recommendations for the severe forms of phlegmon, which involve the fascia and are accompanied by necrosis, so that here the practicality of the guidelines needs to prove its worth over time. The guidelines also give recommendations how to proceed in case of alleged or confirmed hypersensitivity to beta-lactam antibiotics. Currently, relevant guidelines recommend, and it is correspondingly here elaborated, that in acute cases a beta-lactam antibiotic with side chains other than those in the suspected drug may present an alternative without prior testing. Therefore, cefazolin, that does not share any side chains with other beta-lactam antibiotics, could be administered under appropriate precautionary measures. The term cellulitis is avoided in the guidelines. Since it is used frequently, and also for non-infectious dermatoses, the various meanings are discussed and distinguished from each other.


Subject(s)
Soft Tissue Infections , Staphylococcal Infections , Humans , Soft Tissue Infections/diagnosis , Cellulitis/diagnosis , Anti-Bacterial Agents/therapeutic use , Penicillins/therapeutic use , Staphylococcal Infections/drug therapy , Monobactams/therapeutic use
16.
BMJ Case Rep ; 16(10)2023 Oct 17.
Article in English | MEDLINE | ID: mdl-37848276

ABSTRACT

Erysipelothrix rhusiopathiae is a pleomorphic Gram-positive bacillus, zoonotic pathogen of mammals, birds and fish. Human disease caused by this organism most commonly occurs following occupational or recreational exposure to infected animals and typically presents as a localised cutaneous disease. Invasive infection resulting in bacteraemia, endocarditis or other distant sequelae is infrequently seen. Most commonly, invasive infection is seen in patients with predisposing risk factors including diabetes, immunocompromising conditions, alcohol use disorder or chronic kidney disease. The organism is highly susceptible to penicillin-class drugs which serve as first-line antimicrobial therapy with prolonged courses typically prescribed for invasive disease, given the predilection of this organism to cause endocarditis. In this report, we present an interesting case of a polymicrobial finger abscess with E. rhusiopathiae bacteraemia following laceration with a fish spine in an immunocompetent patient in Southern US state. This bacteraemic episode was successfully treated with a fluoroquinolone course owing to patient's penicillin allergy.


Subject(s)
Bacteremia , Endocarditis , Erysipelothrix Infections , Erysipelothrix , Animals , Humans , Erysipelothrix Infections/diagnosis , Erysipelothrix Infections/drug therapy , Cellulitis/drug therapy , Cellulitis/complications , Endocarditis/drug therapy , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/complications , Penicillins/therapeutic use , Seafood/adverse effects , Mammals
17.
Res Vet Sci ; 164: 105032, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37844492

ABSTRACT

Streptococcus uberis is one of the most common pathogens associated with bovine mastitis, commonly treated with antimicrobials (AM), favoring the appearance of antimicrobial resistance (AMR). The objective of this work was to determine the proportion of phenotypic AMR among S. uberis isolated worldwide from bovine intramammary infections between the years 1983-2022, and to assess the variables associated by means of a systematic review and metanalysis. Sixty articles were eligible for quantitative review. Ninety-four independent studies were obtained. The antimicrobials evaluated in more S. uberis strains were penicillin (21,987 strains), oxacillin (21,727 strains), erythromycin (20,013 strains), and ampicillin (19,354 strains). Most of the studies included in this meta-analysis were from Europe (44), followed by America (25), Africa (10), Asia (10), and Oceania (5). Among the included articles, 22 were published from 1983 to 2006, 23 from 2007 to 2012, 25 from 2013 to 2015, and the remaining 24 after 2016. Penicillin, erythromycin, and tetracycline were the antimicrobials with >25 studies. Therefore, the following analyses were performed only for these antimicrobials, presenting a high heterogeneity index (I2). The variability observed for penicillin and tetracycline was only explained, partially, by continent of origin. The variability observed for erythromycin was not explained by any of the potential explanatory variables included in this study. The S. uberis proportion of resistance to antimicrobials is highly variable and probably influenced by many factors other than those studied in this meta-analysis, where it was not possible to inform a unique average proportion of resistance.


Subject(s)
Anti-Infective Agents , Cattle Diseases , Mastitis, Bovine , Streptococcal Infections , Female , Animals , Cattle , Anti-Bacterial Agents/pharmacology , Streptococcal Infections/drug therapy , Streptococcal Infections/veterinary , Mastitis, Bovine/drug therapy , Drug Resistance, Bacterial , Microbial Sensitivity Tests/veterinary , Erythromycin/pharmacology , Tetracycline , Penicillins/pharmacology , Penicillins/therapeutic use
18.
Sci Rep ; 13(1): 17235, 2023 10 11.
Article in English | MEDLINE | ID: mdl-37821503

ABSTRACT

The prevalence of Helicobacter pylori remains high in the older population. Specific age-related peculiarities may impact the outcomes of H. pylori treatment. The aim of the study was to evaluate the diagnostics and effectiveness of H. pylori eradication between the younger and older European populations. "European Registry on H. pylori Management (Hp-EuReg)" data from 2013 to 2022 were analyzed. Patients were divided into older (≥ 60 years) and younger (18-59 years) groups. Modified intention-to-treat (mITT) and per-protocol (PP) analysis was performed. 49,461 patients included of which 14,467 (29%) were older-aged. Concomitant medications and penicillin allergy were more frequent among the older patients. Differences between younger and older populations were observed in treatment duration in first-line treatment and in proton pump inhibitors (PPIs) doses in second-line treatment. The overall incidence of adverse events was lower in the older adults group. The overall first-line treatment mITT effectiveness was 88% in younger and 90% in the older patients (p < 0.05). The overall second-line mITT treatment effectiveness was 84% in both groups. The effectiveness of the most frequent first- and second-line triple therapies was suboptimal (< 90%) in both groups. Optimal efficacy (≥ 90%) was achieved by using bismuth and non-bismuth-based quadruple therapies. In conclusion, the approach to the diagnostics and treatment of H. pylori infection did not generally differ between younger and older patients. Main differences were reported in the concurrent medications, allergy to penicillin and adverse events both in first- and second-line treatment. Optimal effectiveness rates were mostly achieved by using bismuth and non-bismuth-based quadruple therapies. No clinically relevant differences in the effectiveness between the age groups were observed.


Subject(s)
Helicobacter Infections , Helicobacter pylori , Hypersensitivity , Humans , Aged , Helicobacter Infections/drug therapy , Helicobacter Infections/epidemiology , Anti-Bacterial Agents/adverse effects , Bismuth/therapeutic use , Drug Therapy, Combination , Proton Pump Inhibitors/adverse effects , Penicillins/therapeutic use , Treatment Outcome , Hypersensitivity/drug therapy
19.
Article in English | MEDLINE | ID: mdl-37817315

ABSTRACT

The Australian Gonococcal Surveillance Programme (AGSP) has continuously monitored antimicrobial resistance in Neisseria gonorrhoeae for more than 40 years. In 2022, a total of 8,199 isolates from patients in the public and private sectors, in all jurisdictions, were tested for in vitro antimicrobial susceptibility by standardised methods. The current treatment recommendation for gonorrhoea, for the majority of Australia, continues to be dual therapy with ceftriaxone and azithromycin. In 2022, of N. gonorrhoeae isolates tested, 0.51% (42/8,199) met the WHO criterion for ceftriaxone decreased susceptibility (DS), defined as a minimum inhibitory concentration value ≥ 0.125 mg/L. Resistance to azithromycin was reported in 3.9% of N. gonorrhoeae isolates, proportionally stable since 2019. There were nine isolates with high-level resistance to azithromycin (MIC value ≥ 256 mg/L) reported in Australia: Queensland (4), New South Wales (3), Victoria (1) and non-remote Western Australia (1). This is the highest number detected annually by the AGSP. In 2022, penicillin resistance was found in 38.8% of gonococcal isolates, and ciprofloxacin resistance in 63.3%, however, there was considerable variation by jurisdiction. In some remote settings, penicillin resistance remains low; in these settings, penicillin continues to be recommended as part of an empiric therapy strategy. In 2022, in remote Northern Territory, one penicillin-resistant isolate was reported; in remote Western Australia, 11.8% of gonococcal isolates (9/76) were penicillin resistant. There were three ciprofloxacin-resistant isolates reported from remote Northern Territory; ciprofloxacin resistance rates remain comparatively low in remote Western Australia (6/76; 7.9%).


Subject(s)
Anti-Bacterial Agents , Drug Resistance, Multiple, Bacterial , Gonorrhea , Neisseria gonorrhoeae , Humans , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Azithromycin/administration & dosage , Azithromycin/pharmacology , Azithromycin/therapeutic use , Ceftriaxone/administration & dosage , Ceftriaxone/pharmacology , Ceftriaxone/therapeutic use , Ciprofloxacin/pharmacology , Ciprofloxacin/therapeutic use , Gonorrhea/drug therapy , Gonorrhea/epidemiology , Gonorrhea/microbiology , Neisseria gonorrhoeae/drug effects , Neisseria gonorrhoeae/genetics , Penicillins/pharmacology , Penicillins/therapeutic use , Population Surveillance , Microbial Sensitivity Tests , Drug Therapy, Combination , Rural Population/statistics & numerical data , Australia/epidemiology
20.
PLoS One ; 18(10): e0292311, 2023.
Article in English | MEDLINE | ID: mdl-37824534

ABSTRACT

INTRODUCTION: Streptococcal toxic shock syndrome (STSS) is a severe consequence of infections from Streptococcus pyogenes. The early identification and timely intervention with appropriate anti-infective agents are pivotal for managing pediatric STSS. This study evaluates the effectiveness of various treatment regimens for STSS in children. METHODS: Clinical data of children with STSS resulting from ß-hemolytic streptococcal infections in two hospitals were retrospectively analyzed from January 2009 to April 2023. Additionally, literature from the China National Knowledge Infrastructure on pediatric STSS was examined. Antimicrobial treatments were categorized into four groups based on their compositions, with an additional categorization for adjunct therapeutic drugs. RESULTS: Of 32 confirmed STSS cases, all displayed sensitivity to ampicillin, ß-lactam antibiotics, and vancomycin, but resistance to clindamycin, erythromycin, and tetracycline. From the literature, 23 studies with 50 cases were extracted, leading to a total of 82 patients for evaluation. The efficacy rates varied significantly among the four treatment groups. Notably, the standard penicillin-containing group exhibited the highest efficacy (86.4%), while the group with macrolides/unused antibiotics registered a 0% efficacy rate. The other two groups demonstrated efficacy rates of 32.1% and 42.3%. CONCLUSION: For pediatric STSS, Streptococcus pyogenes shows notable sensitivity to ampicillin. Implementing timely ß-lactam antibiotics, specifically penicillin, in conjunction with clindamycin and intravenous immunoglobulins enhances the treatment success rate.


Subject(s)
Shock, Septic , Streptococcal Infections , Humans , Child , Anti-Bacterial Agents/therapeutic use , Clindamycin/therapeutic use , Shock, Septic/drug therapy , Retrospective Studies , Streptococcal Infections/drug therapy , Streptococcus pyogenes , Penicillins/therapeutic use , Ampicillin/therapeutic use , Protein Synthesis Inhibitors/therapeutic use , Macrolides/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...